T1	p 65 88	severe bronchiectasis .
T2	p 254 270	bronchiectasis .
T3	p 416 489	bronchiectasis . Twenty-four patients ( 12 female ; mean age 51 yr ) were
T4	i 14 25	fluticasone
T5	i 98 120	corticosteroid therapy
T6	i 316 334	placebo-controlled
T7	i 393 412	inhaled fluticasone
T8	i 523 599	inhaled fluticasone ( 500 microgram twice daily ) via the Accuhaler device (
T9	i 609 621	or placebo .
T10	i 979 990	fluticasone
T11	i 1007 1018	fluticasone
T12	i 1041 1048	placebo
T13	i 1247 1258	fluticasone
T14	i 1419 1434	steroid therapy
T15	o 34 61	sputum inflammatory indices
T16	o 638 849	spirometry , 24-h sputum volume , sputum leukocyte density , bacterial densities , and concentrations of interleukin ( IL ) -1beta , IL-8 , tumor necrosis factor-alpha ( TNF-alpha ) , and leukotriene B4 ( LTB4 )
T17	o 914 945	in sputum leukocyte density and
T18	o 1125 1135	spirometry
T19	o 1165 1182	adverse reactions
T20	o 1284 1347	the sputum inflammatory indices in bronchiectasis . Large-scale
T21	o 1442 1465	inflammatory components
T22	o 1469 1483	bronchiectasis